Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UBS Maintains Buy on Lennar, Lowers Price Target to $108

UBS analyst John Lovallo maintains Lennar (NYSE:LEN) with a Buy and lowers the price target from $154 to $108.

byBenzinga Newsdesk

June 16, 2022

1 minute read

UBS analyst John Lovallo maintains Lennar (NYSE:LEN) with a Buy and lowers the price target from $154 to $108.

Analyst Ratings

Where Xylem Stands With Analysts

By Benzinga Insights

December 9, 3:01 PM

Over the past 3 months, 9 analysts have published their opinion on Xylem (NYSE:XYL) stock. These analysts are…

XYL

Baird Maintains Neutral on Advanced Micro Devices, Lowers Price Target to $65

By Benzinga Newsdesk

October 7, 8:24 AM

Baird analyst Tristan Gerra maintains Advanced Micro Devices (NASDAQ:AMD) with a Neutral and lowers the price target from $100 to $65.

AMD

Lockheed Martin Names Jay Malave CFO

By Benzinga Newsdesk

February 1, 10:16 AM

Lockheed Martin (NYSE:LMT) announced today that Jesus "Jay" Malave will be the company's next chief financial officer, effective immediately. Malave most recently held the positions of senior vice

LMT

Journal Of Precision Medicine Publication Confirms GeneType Risk Test Outperforms Traditional Risk Assessments For Breast Cancer

By Benzinga Newsdesk

September 29, 8:19 AM

MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and

GENE

UBS Maintains Buy on Lennar, Lowers Price Target to $108

Related Posts

Where Xylem Stands With Analysts

Baird Maintains Neutral on Advanced Micro Devices, Lowers Price Target to $65

Lockheed Martin Names Jay Malave CFO

Journal Of Precision Medicine Publication Confirms GeneType Risk Test Outperforms Traditional Risk Assessments For Breast Cancer